Boehringer Ingelheim Pharmaceuticals, Inc. Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
5/16/2013 7:00:19 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced data from two Phase III clinical trials involving two different investigational oncology compounds – afatinib* and nintedanib* – in two distinct patient populations with advanced non-small cell lung cancer (NSCLC). Results from both studies will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by